MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGTX
CUSIPN/A
Phone646-490-2965
Debt
Debt-to-Equity RatioN/A
Current Ratio11.86
Quick Ratio11.86
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees59
Outstanding Shares27,180,000
Market Cap$319.68 million
MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions
What is MeiraGTx's stock symbol?
MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."
How were MeiraGTx's earnings last quarter?
MeiraGTx Holdings PLC (NASDAQ:MGTX) issued its earnings results on Wednesday, August, 8th. The company reported ($2.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $1.62. View MeiraGTx's Earnings History.
When is MeiraGTx's next earnings date?
What price target have analysts set for MGTX?
4 analysts have issued 12 month price targets for MeiraGTx's stock. Their forecasts range from $20.00 to $21.00. On average, they expect MeiraGTx's share price to reach $20.50 in the next year. This suggests a possible upside of 57.1% from the stock's current price. View Analyst Price Targets for MeiraGTx.
What is the consensus analysts' recommendation for MeiraGTx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.
What are Wall Street analysts saying about MeiraGTx stock?
Here are some recent quotes from research analysts about MeiraGTx stock:
- 1. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (9/18/2018)
- 2. Chardan Capital analysts commented, "We initiate coverage on Buy rating (PT$30), on the forward-looking approach Meira has taken to develop one of the broadest pipelines in AAV-based GT, and one with large- market opportunities, like radiation-induced xerostomia (RIX). At Chardan, we focus coverage on companies with the potential for 5x-10x investment returns through the creation of real value for society. We believe AAV-based gene therapy (GT) player, MeiraGTx, is one such company primed for significant long-term returns as its ocular, salivary, and neurodegenerative diseases franchises contribute to the broader arrival of GT. We believe investors should take notice of the speed of management execution, which will lead to 4 different phase I/II readouts for MeiraGTx in 4 different indications in 2019: i.e." (8/23/2018)
Who are some of MeiraGTx's key competitors?
Some companies that are related to MeiraGTx include Cellectis (CLLS), Autolus Therapeutics (AUTL), Coherus Biosciences (CHRS), Adaptimmune Therapeutics (ADAP), Avrobio (AVRO), Acorda Therapeutics (ACOR), BAVARIAN NORDIC/S (BVNRY), Heska (HSKA), BioCryst Pharmaceuticals (BCRX), Nightstar Therapeutics (NITE), Fate Therapeutics (FATE), Scholar Rock (SRRK), Mesoblast (MESO), Vericel (VCEL) and Voyager Therapeutics (VYGR).
Who are MeiraGTx's key executives?
MeiraGTx's management team includes the folowing people:
- Dr. Alexandria Forbes, CEO, Pres & Director (Age 53)
- Mr. Richard Brian Giroux, Chief Operating Officer (Age 45)
- Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 55)
- Prof. Gregory A. Petsko, Chief Scientist & Chairman of Scientific Advisory Board
- Prof. Robin Ali, Head of Preclinical Ophthalmology & Member of Scientific Advisory Board
When did MeiraGTx IPO?
(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.
When does MeiraGTx's lock-up period expire?
MeiraGTx's lock-up period expires on Wednesday, December 5th. MeiraGTx had issued 5,000,000 shares in its IPO on June 8th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. After the expiration of MeiraGTx's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Has MeiraGTx been receiving favorable news coverage?
News stories about MGTX stock have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MeiraGTx earned a news impact score of 0.18 on Accern's scale. They also gave news coverage about the company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for MeiraGTx.
Who are MeiraGTx's major shareholders?
MeiraGTx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Luminus Management LLC (0.73%), Millennium Management LLC (0.30%), FMR LLC (0.21%), Dean Capital Investments Management LLC (0.15%) and Point72 Asset Management L.P. (0.07%). View Institutional Ownership Trends for MeiraGTx.
Which major investors are buying MeiraGTx stock?
MGTX stock was purchased by a variety of institutional investors in the last quarter, including Luminus Management LLC, Millennium Management LLC, FMR LLC, Dean Capital Investments Management LLC and Point72 Asset Management L.P.. View Insider Buying and Selling for MeiraGTx.
How do I buy shares of MeiraGTx?
Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MeiraGTx's stock price today?
One share of MGTX stock can currently be purchased for approximately $13.05.
How big of a company is MeiraGTx?
MeiraGTx has a market capitalization of $319.68 million. MeiraGTx employs 59 workers across the globe.
How can I contact MeiraGTx?
MeiraGTx's mailing address is 430 EAST 29TH STREET 10TH FLOOR, NEW YORK NY, 10016. The company can be reached via phone at 646-490-2965 or via email at [email protected]
MarketBeat Community Rating for MeiraGTx (NASDAQ MGTX)
MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote "Outperform" if you believe MGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
